Alloy Therapeutics Introduces TEMPER™, a Proprietary siRNA Platform Designed to Advance Targeted Extrahepatic Delivery

Alloy Therapeutics Biogen collaboration

Alloy’s RNA discovery capabilities expanded to include a proprietary differentiated siRNA delivery technology through a strategic transaction with Transcera BOSTON, Mass. – November 17, 2026 – Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to drug discovery technologies and capabilities, today announced the introduction of TEMPER™ (Targeted Extra-Hepatic Modular Precision-Engineered RNA), a proprietary […]

Alloy Therapeutics Selected to Join the World Economic Forum’s Unicorns Community

Alloy will contribute its perspective on building collaborative, AI-powered biotechnology infrastructure to accelerate the discovery and development of better medicines BOSTON — Sept. 17, 2026 — Alloy Therapeutics, a Product Development Organization (PDO), today announced that it has been selected to join the World Economic Forum’s Unicorns Community, an invitation-only group of high-growth private companies […]

Alloy Therapeutics Named a Winner on Fast Company’s 2026 Best Workplaces for Innovators List

BOSTON — September 10, 2026 — Fast Company has named Alloy Therapeutics, Inc. (“Alloy”) a winner on its 2026 Biotech, Healthcare, and Life Sciences list as part of the publication’s eighth annual Best Workplaces for Innovators program. The recognition celebrates organizations that create cultures where innovation can thrive at every level. At Alloy, scientists, operators, and […]

Voro Therapeutics and Alloy Therapeutics Enter Strategic Research Collaboration to Advance Next-Generation Masked T-Cell Engager Therapeutics

Alloy Therapeutics Biogen collaboration

SAN DIEGO & BOSTON – June 18, 2026  – Voro Therapeutics, a biotechnology company developing tumor-activated biologics designed to improve the therapeutic index of immune therapies and Alloy Therapeutics, a biotechnology ecosystem company dedicated to empowering the global biologics community, today announced a strategic research collaboration focused on the discovery and development of next-generation masked T-cell engager […]

Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery

Cryo-Electron Microscopy

Partnership combines world-class protein engineering with scalable drug development to accelerate innovation Boston — May 5, 2026 — Alloy Therapeutics, a leading biotechnology ecosystem company, today announced a strategic collaboration with the Institute for Protein Innovation (IPI), a nonprofit leader in protein engineering and in vitro discovery. Together, the organizations will create bespoke VHH (nanobody) […]

Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure

Alloy Therapeutics Biogen collaboration

BOSTON — April 15, 2026 — Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services, today announced a $40 million Series E financing round, marking a significant step in the company’s evolution from antibody discovery pioneer to full-stack biotech infrastructure company. This […]

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

Boston, MA, April 7, 2026 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense […]

Alloy Therapeutics Appoints Alexander Titus, Ph.D., to Lead New Vigilance Division Focused on Biosecurity and Rapid Therapeutic Response

Cryo-Electron Microscopy

BOSTON — April 1, 2026 — Alloy Therapeutics today announced that Alexander Titus, Ph.D., has joined the company to lead its newly formed Vigilance Division, a strategic initiative focused on leveraging modern AI capabilities to enhance supply chain resilience, advance biosecurity preparedness, and accelerate the development of therapeutics for emerging biological threats.  The Vigilance Division […]

Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform

Alloy Therapeutics antibody discovery platform

BOSTON — March 17, 2026 — Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of […]